相似文献
1
Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study.
Diabetes Care. 2009 Mar;32(3):421-3. doi: 10.2337/dc08-1161. Epub 2008 Dec 10.
2
Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.
Diabetes. 2010 May;59(5):1222-7. doi: 10.2337/db09-1199. Epub 2010 Feb 25.
3
Adiponectin, biomarkers of inflammation and changes in cardiac autonomic function: Whitehall II study.
Cardiovasc Diabetol. 2017 Dec 1;16(1):153. doi: 10.1186/s12933-017-0634-3.
4
Gender-based dimorphic pattern for interleukin-1 receptor antagonist in type 2 diabetes mellitus.
Diabetes Metab. 2008 Feb;34(1):75-81. doi: 10.1016/j.diabet.2007.10.006. Epub 2008 Feb 1.
5
The presence of the 1068 G>A variant of P2X7 receptors is associated to an increase in IL-1Ra levels, insulin secretion and pancreatic β-cell function but not with glycemic control in type 2 diabetes patients.
Gene. 2018 Apr 30;652:1-6. doi: 10.1016/j.gene.2018.01.084. Epub 2018 Feb 6.
6
Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.
Diabetologia. 2011 Jul;54(7):1630-8. doi: 10.1007/s00125-011-2088-6. Epub 2011 Feb 24.
7
Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes.
Gend Med. 2009 Sep;6(3):463-70. doi: 10.1016/j.genm.2009.09.006.
8
Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease: Meta-Analysis of Six Population-Based Cohorts.
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1222-1227. doi: 10.1161/ATVBAHA.117.309307. Epub 2017 Apr 20.
9
Anti-inflammatory cytokines IL-27, IL-10, IL-1Ra and TGF-β in subjects with increasing grades of glucose intolerence (DM-LTB-2).
Cytokine. 2021 Jan;137:155333. doi: 10.1016/j.cyto.2020.155333. Epub 2020 Oct 9.
10
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.
Diabetes Care. 2009 Sep;32(9):1663-8. doi: 10.2337/dc09-0533. Epub 2009 Jun 19.
引用本文的文献
1
Serum IL-1ra Is Associated with but Has No Genetic Link to Type 1 Diabetes.
Endocrines. 2022 Sep;3(3):570-577. doi: 10.3390/endocrines3030048. Epub 2022 Sep 13.
2
Impact of chronic hyperglycaemia on the coronary microcirculation - benefits of targeting IL-36 and diet reversal.
Basic Res Cardiol. 2025 Apr 17. doi: 10.1007/s00395-025-01107-y.
3
Interleukin-1 type 1 receptor blockade attenuates the exaggerated exercise pressor reflex in male UC Davis type 2 diabetic mellitus rats.
J Physiol. 2024 Nov 18. doi: 10.1113/JP287120.
4
Targeting the NLRP3 inflammasome-IL-1β pathway in type 2 diabetes and obesity.
Diabetologia. 2025 Jan;68(1):3-16. doi: 10.1007/s00125-024-06306-1. Epub 2024 Nov 4.
5
Correlations between growth differentiation factor 15 (GDF-15) serum levels and gene polymorphism with type 2 diabetes mellitus.
Heliyon. 2024 Jun 13;10(12):e33044. doi: 10.1016/j.heliyon.2024.e33044. eCollection 2024 Jun 30.
6
Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin.
Pharmaceutics. 2024 Jun 13;16(6):801. doi: 10.3390/pharmaceutics16060801.
7
Integrated Bioinformatics Analysis Revealed Immune Checkpoint Genes Relevant to Type 2 Diabetes.
Diabetes Metab Syndr Obes. 2024 Jun 11;17:2385-2401. doi: 10.2147/DMSO.S458030. eCollection 2024.
8
Nonlinear association of the systemic immune-inflammatory index with mortality in diabetic patients.
Front Endocrinol (Lausanne). 2024 Feb 13;15:1334811. doi: 10.3389/fendo.2024.1334811. eCollection 2024.
9
Causal associations between circulating inflammatory cytokines and blinding eye diseases: a bidirectional Mendelian randomization analysis.
Front Aging Neurosci. 2024 Jan 23;16:1324651. doi: 10.3389/fnagi.2024.1324651. eCollection 2024.
10
Native low-density lipoproteins are priming signals of the NLRP3 inflammasome/interleukin-1β pathway in human adipose tissue and macrophages.
Sci Rep. 2023 Nov 1;13(1):18848. doi: 10.1038/s41598-023-45870-1.
本文引用的文献
1
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.
Endocrinology. 2008 May;149(5):2208-18. doi: 10.1210/en.2007-1059. Epub 2008 Jan 31.
2
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
Diabetes Care. 2008 Feb;31 Suppl 2:S161-4. doi: 10.2337/dc08-s243.
3
Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002.
Diabetologia. 2008 Feb;51(2):276-84. doi: 10.1007/s00125-007-0800-3. Epub 2007 Aug 22.
4
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
N Engl J Med. 2007 Apr 12;356(15):1517-26. doi: 10.1056/NEJMoa065213.
5
Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects.
Diabetes Care. 2006 Dec;29(12):2714-20. doi: 10.2337/dc06-0147.
6
The adipocyte-myocyte axis in insulin resistance.
Trends Endocrinol Metab. 2006 Dec;17(10):416-22. doi: 10.1016/j.tem.2006.10.010. Epub 2006 Nov 3.
7
Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.
Diabetologia. 2006 May;49(5):921-9. doi: 10.1007/s00125-006-0190-y. Epub 2006 Mar 11.
8
An immune origin of type 2 diabetes?
Diabetologia. 2005 Jun;48(6):1038-50. doi: 10.1007/s00125-005-1764-9. Epub 2005 Apr 30.
9
Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome.
Circulation. 2004 Dec 21;110(25):3842-8. doi: 10.1161/01.CIR.0000150391.38660.9B. Epub 2004 Dec 13.
10
Cohort Profile: the Whitehall II study.
Int J Epidemiol. 2005 Apr;34(2):251-6. doi: 10.1093/ije/dyh372. Epub 2004 Dec 2.
Zotero 插件